牛牛AI助理已提取核心訊息
Kathryn E Wengel, EVP, Chief TO and Risk Officer at Johnson & Johnson, was involved in a transaction with the company's stock on February 15, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action type and status of the transaction were also not provided. This information is essential for investors to understand the implications of the transaction on their investment decisions.
Kathryn E Wengel, EVP, Chief TO and Risk Officer at Johnson & Johnson, was involved in a transaction with the company's stock on February 15, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action type and status of the transaction were also not provided. This information is essential for investors to understand the implications of the transaction on their investment decisions.
強生公司執行副總裁、首席技術官兼風險官凱瑟琳·溫格爾於2024年2月15日參與了該公司股票的交易。公告中未披露該交易的具體細節，包括股票數量、股票性質、交易價格和股票總價值。也沒有提供交易的操作類型和狀態。這些信息對於投資者了解交易對其投資決策的影響至關重要。
強生公司執行副總裁、首席技術官兼風險官凱瑟琳·溫格爾於2024年2月15日參與了該公司股票的交易。公告中未披露該交易的具體細節，包括股票數量、股票性質、交易價格和股票總價值。也沒有提供交易的操作類型和狀態。這些信息對於投資者了解交易對其投資決策的影響至關重要。
有用
沒用